Pieris Corp (PVLA) - מקדם חוב לטווח ארוך להון

This chart of current Pieris Pharmaceuticals (PVLA) quotes on the GURU.Markets platform, where the indicator stands at 0.09, depends on the transition of production to eco-friendly closed-loop cycles. The business, which develops immune drugs, is currently undergoing a non-profitable restructuring under a strict R&D spending limit. Meanwhile, assets remain crisis-resistant, as the success of molecules is independent of economic conditions.

The success of Pieris Pharmaceuticals (PVLA) depends on clinical trials and strategic alliances, rendering the company independent of economic cycles. The long-term debt-to-equity ratio measures financial leverage, where the market value of shares constantly adjusts the denominator, allowing investors to determine the balance between default risks and business growth potential through the assessment of long-term debt to equity.